The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 biomarker-driven study of ipilimumab plus nivolumab (Ipi/Nivo) for ARV7-positive metastatic castrate-resistant prostate cancer (mCRPC).
 
Karim Boudadi
No Relationships to Disclose
 
Daniel L. Suzman
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; GE Healthcare; Trillium Therapeutics
Honoraria - Grand Rounds Health
 
Brandon Luber
No Relationships to Disclose
 
Hao Wang
No Relationships to Disclose
 
John Silberstein
No Relationships to Disclose
 
Rana Sullivan
No Relationships to Disclose
 
Donna Dowling
No Relationships to Disclose
 
Rana Harb
No Relationships to Disclose
 
Thomas Nirschl
Research Funding - Janssen Oncology (Inst)
 
Ryan Vance Dittamore
Employment - Epic Sciences
Leadership - Epic Sciences
Stock and Other Ownership Interests - Epic Sciences
Patents, Royalties, Other Intellectual Property - Patents Pending
 
Michael Anthony Carducci
Consulting or Advisory Role - Astellas Pharma; Churchill Pharmaceuticals; Medivation; Merck
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); pfizer (Inst)
 
Mario A. Eisenberger
Honoraria - pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Ipsen; pfizer; Sanofi; Sanofi
Research Funding - Genentech; Sanofi; Tokai Pharmaceuticals
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Pfizer; Sanofi
 
Michael Haffner
No Relationships to Disclose
 
Alan Meeker
No Relationships to Disclose
 
James R. Eshleman
No Relationships to Disclose
 
Jun Luo
Honoraria - Gilead Sciences; Sanofi
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; Tokai Pharmaceuticals
Research Funding - Astellas Pharma (Inst); Gilead Sciences (Inst); Mirati Therapeutics (Inst); Orion (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Jun Luo is a co-inventor of a technology assigned to Johns Hopkins University who licensed to Tokai Pharmaceuticals. (Inst)
 
Charles G. Drake
Stock and Other Ownership Interests - Compugen; ImmunExcite; NexImmune; Potenza Therapeutics; Tizona Therapeutics, Inc.
Consulting or Advisory Role - Agenus; Astellas Medivation; AstraZeneca/MedImmune; Bristol-Myers Squibb (Inst); Compugen; Dendreon; ImmuneXcite; Janssen Oncology; Lilly; Merck; NexImmune; Pfizer; Pierre Fabre; Potenza Therapeutics; Roche/Genentech; Tizona Therapeutics, Inc.
Research Funding - Aduro Biotech (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Janssen Oncology (Inst)
Patents, Royalties, Other Intellectual Property - Patents licensed to BMS (Inst); Patents licensed to Potenza Therapeutics (Inst)
 
Emmanuel S. Antonarakis
Honoraria - Astellas Pharma; Dendreon; ESSA; Janssen Biotech; Medivation; Sanofi
Consulting or Advisory Role - Astellas Pharma; Dendreon; ESSA; Janssen Biotech; Medivation; Sanofi
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi